Noah Doyle - Net Worth and Insider Trading
Noah Doyle Net Worth
The estimated net worth of Noah Doyle is at least $13,308 dollars as of 2024-11-13. Noah Doyle is the Director of Ritter Pharmaceuticals Inc and owns about 29,573 shares of Ritter Pharmaceuticals Inc (RTTR) stock worth over $13,308. Details can be seen in Noah Doyle's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Noah Doyle has not made any transactions after 2020-03-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Noah Doyle
Noah Doyle Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Noah Doyle owns 2 companies in total, including Ritter Pharmaceuticals Inc (RTTR) , and Qualigen Therapeutics Inc (QLGN) .
Click here to see the complete history of Noah Doyle’s form 4 insider trades.
Insider Ownership Summary of Noah Doyle
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
RTTR | Ritter Pharmaceuticals Inc | 2020-03-12 | director |
QLGN | Qualigen Therapeutics Inc | 2019-02-25 | director |
Noah Doyle Latest Holdings Summary
Noah Doyle currently owns a total of 1 stock. Noah Doyle owns 29,573 shares of Ritter Pharmaceuticals Inc (RTTR) as of March 12, 2020, with a value of $13,308.
Latest Holdings of Noah Doyle
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
RTTR | Ritter Pharmaceuticals Inc | 2020-03-12 | 29,573 | 0.45 | 13,308 |
Holding Weightings of Noah Doyle
Noah Doyle Form 4 Trading Tracker
According to the SEC Form 4 filings, Noah Doyle has made a total of 1 transactions in Ritter Pharmaceuticals Inc (RTTR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Ritter Pharmaceuticals Inc is the sale of 20,000 shares on March 12, 2020, which brought Noah Doyle around $110,000.
Insider Trading History of Noah Doyle
- 1
Noah Doyle Trading Performance
GuruFocus tracks the stock performance after each of Noah Doyle's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Noah Doyle is -41.53%. GuruFocus also compares Noah Doyle's trading performance to market benchmark return within the same time period. The performance of stocks bought by Noah Doyle within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Noah Doyle's insider trading performs compared to the benchmark.
Performance of Noah Doyle
Noah Doyle Ownership Network
Ownership Network List of Noah Doyle
Ownership Network Relation of Noah Doyle
Noah Doyle Owned Company Details
What does Ritter Pharmaceuticals Inc do?
Who are the key executives at Ritter Pharmaceuticals Inc?
Noah Doyle is the director of Ritter Pharmaceuticals Inc. Other key executives at Ritter Pharmaceuticals Inc include 10 percent owner Sekisui Diagnostics, Llc , director & Chairman & President & CEO Michael S. Poirier , and Vice President of Finance & CFO Christopher L. Lotz .
Ritter Pharmaceuticals Inc (RTTR) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Ritter Pharmaceuticals Inc (RTTR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ritter Pharmaceuticals Inc (RTTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Ritter Pharmaceuticals Inc (RTTR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ritter Pharmaceuticals Inc Insider Transactions
Noah Doyle Mailing Address
Above is the net worth, insider trading, and ownership report for Noah Doyle. You might contact Noah Doyle via mailing address: C/o Ritter Pharmaceuticals Inc., 1801 Century Park East, Suite 1820, Los Angeles Ca 90096.